Skip to main content

 

Baricitinib (Olumiant®) for the treatment of chronic severe atopic dermatitis (AD) - 25 May 2021

Allergy & Anaphylaxis Australia made a submission to to Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme (PBAC) listing of Baricitinib (Olumiant®) for the treatment of chronic severe atopic dermatitis (AD).

pdfA&AA Baricitinib Olumiant Submission May 2021167.27 KB

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.